2024
Quadrivalent Conjugate Vaccine and Invasive Meningococcal Disease in US Adolescents and Young Adults
Shin T, Wells C, Shoukat A, Potter-Schwartz L, Langevin E, Langley J, Galvani A, Moghadas S. Quadrivalent Conjugate Vaccine and Invasive Meningococcal Disease in US Adolescents and Young Adults. JAMA Network Open 2024, 7: e2443551. PMID: 39504021, PMCID: PMC11541638, DOI: 10.1001/jamanetworkopen.2024.43551.Peer-Reviewed Original ResearchConceptsInvasive meningococcal diseaseInvasive meningococcal disease casesCases of invasive meningococcal diseaseQuadrivalent conjugate vaccineUS adolescentsMeningococcal diseaseConjugate vaccineMenACWY vaccineIncidence rates of invasive meningococcal diseasePrevention of invasive meningococcal diseaseIncidence rateBurden of meningococcal diseaseUS adolescent populationUS populationYoung adultsImmunization of adolescentsIncidence of invasive meningococcal diseaseBayesian hierarchical Poisson regression modelsDecision analytical studyRate of invasive meningococcal diseaseMenACWY vaccination programUnvaccinated individualsDecision analytic modelHierarchical Poisson regression modelYears of age
2023
Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study
Shoukat A, Abdollahi E, Galvani A, Halperin S, Langley J, Moghadas S. Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study. The Lancet Regional Health - Americas 2023, 28: 100629. PMID: 38026446, PMCID: PMC10663690, DOI: 10.1016/j.lana.2023.100629.Peer-Reviewed Original ResearchEntire birth cohortPregnant womenBirth cohortCost-effectiveness analysisRSV seasonHigh riskBudget impactRespiratory syncytial virus diseaseSocietal perspectiveAnnual budget impactFirst RSV seasonHealth benefitsRespiratory syncytial virusImmunisation of infantsYears of ageLow budget impactMonths of ageNet monetary benefitMaternal vaccinesRSV infectionPassive immunisationGestational ageImmunisation strategiesSyncytial virusVaccine strategies